Top Stories
Top Stories

Cramer Remix: The black hole that investors are just waking up to

Cramer Remix: This is a black hole investors are just waking up to

Chills ran down Jim Cramer's spine when he learned that General Mills guided down for its first fiscal quarter. He saw that safety stocks have now become very dangerous.

"This safety group may prove to be the most vulnerable out there at the moment, until the stocks come down to the point where their yields offer more support and the takeover chatter ends," the "Mad Money" host said.

Cramer does not often see a stock like General Mills drop $3 like it did on Wednesday. The company cited rising competition in its yogurt business as it cut August guidance, which reminded Cramer of just how much of a battleground supermarkets are right now.

Cramer wondered when the supermarket pressure would trickle down to consumer packaged goods stocks. They have rallied so much in the past few years that their dividend yields now look unimpressive.

"The deflation in food is the black hole that investors are just waking up to," Cramer said.

For those investors that own stocks like Kellogg, ConAgra, Church & Dwight, Kimberly-Clark or Clorox, Cramer says to keep one finger on the trigger.

A trader works on the floor of the New York Stock Exchange (NYSE).
Getty Images

The market's reaction to oil inventories on Thursday told Cramer that it really only has the ability to focus on one bullish idea at a time and dumps everything else.

"When you have a market that decides only one thing is working, and it doesn't bother with anything else, you have a market that is a lot more treacherous than it seems," he said.

The price of crude shot up on Thursday after oil inventories indicated a large drawdown of 14.5 million barrels. But the market's one-track mind creates a problem. It tends to favor one group, then punish the others.

"Lots of companies and sectors are laying down on the tracks, so to speak, almost in order to facilitate the smooth train ride for the oils," Cramer said.

Ultimately, Cramer sees a one-track mind market as a treacherous one. After all, the market could be totally irrational, as it has been so many times before.

David McNew | Getty Images

Cramer always has his eye out for the next big idea, especially privately-held companies making big waves in their industry. His attention recently turned to Blaze Pizza, backed by basketball superstar LeBron James.

In 2015, James decided not to renew his deal with McDonald's and instead endorsed Blaze Pizza. In an interview on "Mad Money," Blaze's Chief Operating Officer Jim Mizes chronicled the evolution of James's involvement with the company from investor to spokesperson and now a franchisee partnered with Larry Levy.

"He saw what Blaze Pizza and what this category could be, so he started as an investor, and then became a franchisee … And then he was so into Blaze that he came all in," Mizes said.

With this year an ugly one for biotech, situations like the one with Mylan's EpiPen have thrust drug pricing back into the public eye.

But that doesn't mean every biotech company is struggling. Spark Therapeutics has continued to be an outperformer. It was created in 2013 through the acquisition of intellectual property rights for various programs from the Children's Hospital of Philadelphia and other institutions.

Spark is a developmental stage biotech that is focused on gene therapy, with a stock that is up nearly 30 percent for the year. Cramer spoke with Spark's co-founder and CEO Jeff Marrazzo, who confirmed positive top-line results for a product used to treat the retinal dystrophies, a genetic condition that causes reduced or deteriorating vision.

"Last year we completed successfully a phase three clinical trial. It was .. a pivotal trial that was randomized and controlled for gene therapy in a genetic disease," Marrazzo said. "That is a significant milestone, and we now are busy preparing and are near substantial completion of the first marketing authorization submission that we have put to the FDA."

In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:

Brightcove: "Brightcove I think is a little risky. It's making a lot of money there and the stock has had a very big run. My take is don't buy, don't buy."

Sarepta Therapautics: "This is one of the highest risk stocks in the world. It's a binary stock; they either get approval or they don't. If they get approval, the stock has still doubled from $28. And if they don't get approval the stock can get crushed. I think it's way too risky for me."